Business context and reporting period
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on neuroscience and oncology. This Form 10-K reports the fiscal year ended December 31, 2021; it is an annual report, not a standalone fourth-quarter filing. Results include GW Pharmaceuticals from its May 5, 2021 acquisition, acquired for approximately $7.2 billion.
Key products include Xyrem and Xywav, Epidiolex/Epidyolex, Sunosi, Zepzelca, Rylaze, Vyxeos and Defitelio. Management’s January 2022 Vision 2025 priorities are commercial execution, pipeline productivity and operational excellence.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $3.094 billion | $2.364 billion |
| Net product sales | $3.079 billion | $2.347 billion |
| Income from operations | $170.3 million | $378.1 million |
| Net income (loss) | $(329.7) million | $238.6 million |
| Net cash from operating activities | $778.5 million | $899.6 million |
| Gross margin | 85.7% | 93.7% |
Revenue rose 31%, reflecting the GW acquisition and growth in newer products. Product sales were 99% of total revenue. Xyrem remained the largest product at $1.266 billion; Xywav contributed $535.3 million, Epidiolex/Epidyolex $463.6 million (May–December only), and oncology products included Zepzelca at $246.8 million, Defitelio/defibrotide at $197.9 million, Vyxeos at $134.1 million and Rylaze at $85.6 million. Xyrem sales fell 27%, largely as patients transitioned to Xywav; total oxybate sales increased 3%.
Profitability weakened despite higher revenue: operating income declined, and the company reported a net loss. Operating expenses increased substantially, including acquired-product amortization, GW-related costs and inventory fair-value step-up costs. Interest expense rose to $278.8 million from $99.7 million.
Cash and equivalents were $591.4 million at year-end, with a $500 million undrawn revolving facility. Debt principal was approximately $6.4 billion (carrying amount $6.05 billion). Operating cash flow declined 13%; investing cash outflow was $5.21 billion, principally reflecting $6.23 billion net cash paid for GW. Financing provided $3.97 billion. Management stated existing cash, operating cash flow and revolver availability should fund operations and obligations for the foreseeable future.
Material changes versus the prior year
- GW expanded the neuroscience portfolio and materially increased assets, including $5.48 billion of acquired developed technology, primarily Epidiolex. Its results were included from May 5; the acquired business contributed $476.4 million revenue and a $704.6 million net loss for that post-close period.
- Gross margin fell from 93.7% to 85.7%, primarily due to acquisition-accounting inventory step-up expense. $223.1 million of step-up expense was recognized in 2021; $811.3 million of step-up inventory remained on the year-end balance sheet.
- SG&A increased 70% to $1.452 billion, including $229 million of transaction and integration-related expenses, higher headcount and commercial investment. R&D increased 51% to $505.7 million.
- Income tax expense was $216.1 million versus $33.5 million. The 2021 amount included a $259.9 million charge from remeasuring the U.K. net deferred tax liability after a statutory rate change, primarily related to the GW acquisition.
- Net product sales deductions rose to $656.3 million, or 17.6% of gross sales, from $421.4 million, or 15.2%, reflecting rebates, new commercial payor arrangements and portfolio mix.
Outlook, commentary, risks and contingencies
Management expects 2022 net product sales to increase, primarily from Xywav growth, a full year of Epidiolex and Rylaze sales, and Zepzelca growth, partly offset by lower Xyrem sales as patients transition to Xywav. It expects royalties and contract revenue to increase. Management anticipates lower SG&A as transaction and integration spending subsides and synergies emerge, partly offset by a full year of GW costs; R&D, amortization and cost of product sales are expected to increase. No numerical 2022 revenue or earnings guidance is provided in the supplied filing text.
- Oxybate concentration and competition: Xywav and Xyrem together generated $1.8 billion, about 58% of 2021 product sales. Generic/authorized-generic entry is expected under settlements beginning as early as 2023, subject to acceleration provisions. Lupin challenged Xywav patents; Jazz sued. The Avadel extended-release oxybate application remained under FDA review, and Jazz has patent litigation pending against Avadel.
- Regulatory and clinical risk: Zepzelca has accelerated FDA approval and requires confirmatory evidence of clinical benefit; failure could jeopardize approval. The confirmatory second-line SCLC study began in December 2021. Other pipeline programs remain subject to clinical and regulatory uncertainty.
- Supply and pandemic risks: COVID-19 continued to constrain diagnosis, new patient starts and healthcare access. Jazz expected adequate global product supply for 2022, but disclosed single-source suppliers and manufacturing complexity, particularly for Vyxeos and certain cannabinoid products.
- Legal matters: Xyrem purchasers filed antitrust and consumer-protection claims concerning patent settlements; proceedings were consolidated for pretrial matters. Otsuka asserted a royalty claim relating to Epidiolex. Canopy’s Epidiolex-process patent case resulted in judgment for GW in February 2022, with Canopy retaining appeal rights. Outcomes and potential financial effects are uncertain.
- Other financial risks: High leverage, variable-rate borrowing, pricing and reimbursement pressure, patent challenges, integration execution and impairment risk could affect results. Management reported effective disclosure controls and internal control over financial reporting; KPMG issued unqualified opinions on the financial statements and internal controls.
Investor facts to verify
- Review the reconciliation of 2021 net loss and the impact of GW-related amortization, inventory step-up, integration costs and the U.K. deferred-tax remeasurement.
- Track Xywav adoption and whether Xyrem declines are offset by Xywav growth, alongside the timing and terms of generic oxybate entry.
- Assess debt repayment capacity, floating-rate exposure, covenants and the planned pace of deleveraging against operating cash flow.
- Monitor Epidiolex growth, Zepzelca’s confirmatory trial, and Rylaze’s dosing and geographic expansion plans.
- Follow the Xyrem antitrust litigation, Xywav and Avadel patent disputes, and Otsuka’s royalty claim, including any disclosed changes to expected exposure.